Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.88
NSPH's Cash to Debt is ranked higher than
72% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. NSPH: 1.88 )
NSPH' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 1.88

Equity to Asset 0.60
NSPH's Equity to Asset is ranked higher than
72% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NSPH: 0.60 )
NSPH' s 10-Year Equity to Asset Range
Min: -5.28   Max: 0.94
Current: 0.6

-5.28
0.94
F-Score: 5
Z-Score: -13.48
M-Score: -1.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -313.85
NSPH's Operating margin (%) is ranked lower than
51% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. NSPH: -313.85 )
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.06   Max: -337.14
Current: -313.85

-2890.06
-337.14
Net-margin (%) -326.19
NSPH's Net-margin (%) is ranked lower than
51% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.09 vs. NSPH: -326.19 )
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.67   Max: -346.4
Current: -326.19

-4551.67
-346.4
ROE (%) -102.75
NSPH's ROE (%) is ranked higher than
51% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. NSPH: -102.75 )
NSPH' s 10-Year ROE (%) Range
Min: -2681.37   Max: -40.32
Current: -102.75

-2681.37
-40.32
ROA (%) -71.01
NSPH's ROA (%) is ranked higher than
50% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. NSPH: -71.01 )
NSPH' s 10-Year ROA (%) Range
Min: -466.5   Max: -34.8
Current: -71.01

-466.5
-34.8
ROC (Joel Greenblatt) (%) -340.20
NSPH's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.33 vs. NSPH: -340.20 )
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -733.73   Max: -436.6
Current: -340.2

-733.73
-436.6
Revenue Growth (%) 31.70
NSPH's Revenue Growth (%) is ranked higher than
97% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. NSPH: 31.70 )
NSPH' s 10-Year Revenue Growth (%) Range
Min: -73.2   Max: 49.9
Current: 31.7

-73.2
49.9
EBITDA Growth (%) -27.30
NSPH's EBITDA Growth (%) is ranked higher than
53% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. NSPH: -27.30 )
NSPH' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 34.8
Current: -27.3

0
34.8
EPS Growth (%) -27.30
NSPH's EPS Growth (%) is ranked higher than
54% of the 241 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. NSPH: -27.30 )
NSPH' s 10-Year EPS Growth (%) Range
Min: -69.8   Max: 48.1
Current: -27.3

-69.8
48.1
» NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NSPH Guru Trades in Q3 2013

Louis Moore Bacon 75,000 sh (New)
John Keeley 26,000 sh (New)
Paul Tudor Jones 18,800 sh (New)
» More
Q4 2013

NSPH Guru Trades in Q4 2013

John Keeley 26,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2014

NSPH Guru Trades in Q1 2014

John Keeley 26,000 sh (unchged)
» More
Q2 2014

NSPH Guru Trades in Q2 2014

Jim Simons 156,864 sh (New)
George Soros 58,000 sh (New)
John Keeley 26,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.23 - $2.25 $ 0.58-64%58000
John Keeley 2013-09-30 New Buy$1.83 - $3.44 $ 0.58-77%26000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.76
NSPH's P/B is ranked higher than
84% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. NSPH: 1.76 )
NSPH' s 10-Year P/B Range
Min: 0.82   Max: 7.31
Current: 1.76

0.82
7.31
P/S 3.49
NSPH's P/S is ranked higher than
69% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. NSPH: 3.49 )
NSPH' s 10-Year P/S Range
Min: 3.28   Max: 188.83
Current: 3.49

3.28
188.83
EV-to-EBIT -0.90
NSPH's EV-to-EBIT is ranked higher than
60% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. NSPH: -0.90 )
NSPH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.9

Current Ratio 3.86
NSPH's Current Ratio is ranked higher than
84% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. NSPH: 3.86 )
NSPH' s 10-Year Current Ratio Range
Min: 0.63   Max: 20.13
Current: 3.86

0.63
20.13
Quick Ratio 2.70
NSPH's Quick Ratio is ranked higher than
82% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. NSPH: 2.70 )
NSPH' s 10-Year Quick Ratio Range
Min: 0.61   Max: 19.52
Current: 2.7

0.61
19.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.67
NSPH's Price/Net Cash is ranked higher than
92% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NSPH: 9.67 )
NSPH' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 27.5
Current: 9.67

1.05
27.5
Price/Net Current Asset Value 3.62
NSPH's Price/Net Current Asset Value is ranked higher than
94% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NSPH: 3.62 )
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 1.02   Max: 10.31
Current: 3.62

1.02
10.31
Price/Tangible Book 1.93
NSPH's Price/Tangible Book is ranked higher than
88% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.41 vs. NSPH: 1.93 )
NSPH' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 6.14
Current: 1.93

0.88
6.14
Price/Median PS Value 0.11
NSPH's Price/Median PS Value is ranked higher than
99% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. NSPH: 0.11 )
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 4.42
Current: 0.11

0.3
4.42
Forward Rate of Return (Yacktman) -183.94
NSPH's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 266 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.14 vs. NSPH: -183.94 )
NSPH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 22.3   Max: 55.8
Current: -183.94

22.3
55.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:3NS.Germany
Nanosphere, Inc., is a Delaware Corporation. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. While many systems currently available on the market provide a diagnostic result for one test or a few tests within a specific market niche, the Verigene System provides for multiple tests to be performed on a single platform, including both genomic and protein assays, from a single sample. The Verigene System is differentiated by its ease of use, rapid turnaround times and ability to detect many targets on a single test, referred to as 'multiplexing.' It provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
» More Articles for NSPH

Headlines

Articles On GuruFocus.com
comment on NSPH Mar 02 2013 
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Sep 30 2014
NANOSPHERE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Sep 22 2014
New Outcomes Data Presented at ICAAC 2014 Further Validates Clinical and Economic Utility of... Sep 08 2014
Nanosphere (NSPH) Slumps: NSPH Plunges 14.3% in Session Sep 05 2014
NANOSPHERE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 04 2014
Nanosphere Announces Review of Strategic Alternatives Sep 04 2014
New Clinical and Economic Outcome Data for Verigene Blood Culture Test to Be Presented at ICAAC 2014 Sep 02 2014
NANOSPHERE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 20 2014
Nanosphere Appoints Kristopher Wood to Its Board of Directors Aug 20 2014
NANOSPHERE INC Financials Aug 19 2014
Why Nanosphere (NSPH) Stock Hit a One-Year Low Today Aug 07 2014
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2014
Nanosphere Announces Second Quarter Financial and Operating Results Aug 06 2014
Q2 2014 NANOSPHERE INC Earnings Release - Time Not Supplied Aug 06 2014
Nanosphere to Release Second Quarter Results and Host Investor Conference Call on Wednesday, August... Jul 23 2014
Why Nanosphere (NSPH) Stock Is Surging Today Jun 25 2014
NANOSPHERE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 25 2014
Nanosphere (NSPH) Jumps: Stock Rises 14.6% Jun 24 2014
Why Nanosphere (NSPH) Stock Is Surging Today Jun 23 2014
NANOSPHERE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK